SCHEMBL16216079

SCHEMBL16216079

CCC[N+]1(C)CCN(c2ccc(F)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.45
MAPK1 P28482 2/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
GFER P55789 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CYP3A4 P08684 1/20 0.44
ALOX15 P16050 1/20 0.44
CHRNB2 P17787 1/20 0.44
NFKB1 P19838 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA4 P43681 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CHRNA10 Q9GZZ6 1/20 0.43
CHRNA9 Q9UGM1 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19361277 0.87 MAPK1 (0.44) CHRNA7MAPK1ALDH1A1LMNAMAPT
SCHEMBL10105155 0.84 CHRNA7 (0.63) CHRNA7MAPK1ALDH1A1LMNAGFER
Iodide SCHEMBL17144379 0.78 KMT2A (0.57) CHRNA7MAPK1ALDH1A1GFERCYP3A4
Iodide SCHEMBL18741387 0.76 CHRNA10 (0.66) CHRNA7MAPK1ALDH1A1LMNAMAPT
SCHEMBL17151191 0.72 CHRNA7 (0.60) CHRNA7MAPK1ALDH1A1LMNAMAPT
SCHEMBL10373626 0.71 MAPT (0.77) MAPK1ALDH1A1LMNAMAPTHTT
SCHEMBL10115138 0.70 CHRNA7 (0.73) CHRNA7MAPK1LMNACYP3A4ALOX15
SCHEMBL5915112 0.70 DRD2 (0.68) MAPK1ALDH1A1LMNAMAPTHTT
SCHEMBL21254005 0.70 CHRNA7 (0.44) CHRNA7MAPK1LMNAMAPTCYP3A4
SCHEMBL7903765 0.69 MAPT (0.67) CHRNA7MAPK1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170266326-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2017-09-21 US disclosed
US-9550000-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2017-01-24 US disclosed
US-20140328756-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2014-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170266326-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 CHRNA7 1882/4885MAPK1 4646/4885ALDH1A1 2699/4885
US-20140328756-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 CHRNA7 1882/4885MAPK1 4646/4885ALDH1A1 2699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.